Screening for hemochromatosis: High prevalence and low morbidity in an unselected population of 65,238 persons

Scandinavian Journal of Gastroenterology

Volumn 36, Issue 10, 2001, Pages 1108-1115

  Asberg A ^a   Hveem, K ^a   Thorstensen, K ^a   Ellekjaer E ^a   Kannelonning K ^a   Fjosne U ^a   Halvorsen, T B ^a   Smethurst, H B G ^a   Sagen, E ^a   Bjerve, K S ^a  

^a TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

Author keywords

Cost benefit; Hemochromatosis; Screening

Indexed keywords

ADULT; AGED; ARTICLE; BLOOD SAMPLING; COST BENEFIT ANALYSIS; FEMALE; GENE MUTATION; HEALTH SURVEY; HEMOCHROMATOSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; NORWAY; PHLEBOTOMY; POPULATION RESEARCH; PREVALENCE; PRIORITY JOURNAL; SCREENING TEST; TRANSFERRIN BLOOD LEVEL;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BIOPSY; COST-BENEFIT ANALYSIS; FEMALE; FERRITINS; HEMOCHROMATOSIS; HUMANS; LIVER; LIVER CIRRHOSIS; MALE; MASS SCREENING; MIDDLE AGED; NORWAY; PREVALENCE; TRANSFERRIN;

EID: 17944369464     PISSN: 00365521     EISSN: None     Source Type: Journal    
DOI: 10.1080/003655201750422747     Document Type: Article

References (42)

1. Haemochromatosis in the new millennium
2. Screening for hemochromatosis
3. Preventing manifestations of hereditary haemochromatosis through population-based screening
4. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis
5. Global prevalence of putative haemochromatosis mutations
6. Molecular medicine and hemochromatosis: At the crossroads
7. Epidemiology, clinical spectrum and prognosis of hemochromatosis
8. Clinical spectrum and management of haemochromatosis
9. Long-term survival in patients with hereditary hemochromatosis
10. Practice guideline development task force of the College of American Pathologists. Hereditary hemochromatosis
11. Hereditary hemochromatosis: Gene discovery and its implications for population-based screening
12. Cost-effectiveness analysis for evaluation of screening programs: Hereditary hemochromatosis
13. Cost-effectiveness of screening for hereditary hemochromatosis
14. Screening blood donors for hereditary hemochromatosis: Decision analysis model based on a 30-year database
15. Prevalence of hemochromatosis in Finland
16. Screening for haemochromatosis: Prevalence among Danish blood donors
17. Prevalence of hemochromatosis among first-time and repeat blood donors in Norway
18. Population screening for hemochromatosis: A comparison of unbound iron-binding capacity, transferrin saturation, and C282Y genotyping in 5,211 voluntary blood donors
19. Hemochromatosis screening in asymptomatic ambulatory men 30 years of age and older
20. Screening for hemochromatosis: A cost-effectiveness study based on 12,258 patients
21. Prevalence of hereditary haemochromatosis in two Swedish urban areas
22. Automated measurement of unsaturated iron binding capacity is an effective screening strategy for C282Y homozygous haemochromatosis
23. Prevalence of hereditary hemochromatosis in 16031 primary care patients
24. AACC meeting abstract
25. Iron storage disease
26. Polymorphism in intron 4 of HFE may cause overestimation of C282Y homozygote prevalence in haemochromatosis
27. EASL International Consensus Conference on Haemochromatosis
28. Value of hepatic iron measurements in early hemochromatosis and determination of the critical iron level associated with fibrosis
29. Screening for hemochromatosis and iron deficiency in employees and primary care patients in Western Germany
30. Population-based screening for hemochromatosis using phenotypic and DNA testing among employees of health maintenance organizations in Springfield, Missouri
31. High prevalence of the hemochromatosis-associated Cys282Tyr HFE gene mutation in a healthy Norwegian population in the city of Oslo, and its phenotypic expression
32. HFE gene mutation (C282Y) and phenotypic expression among a hospitalised population in a high prevalence area of haemochromatosis
33. A population-based study of the clinical expression of the hemochromatosis gene
34. The clinical expression of hemochromatosis in Oslo, Norway. Excessive oral iron intake may lead to secondary hemochromatosis even in HFE C282Y mutation negative subjects
35. HFE mutations in patients with hereditary haemochromatosis in Sweden
36. Iron overload, public health, and genetics: Evaluating the evidence for hemochromatosis screening
37. The relationship between iron overload, clinical symptoms, and age in 410 patients with genetic hemochromatosis